Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lixte Biotechnology Holdings Inc WT (LIXTW)

Lixte Biotechnology Holdings Inc WT (LIXTW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ -6,010 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/11/26 [--]
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0100 +400.00%
on 11/24/25
0.1699 -70.57%
on 10/29/25
-0.1099 (-68.73%)
since 10/28/25
3-Month
0.0100 +400.00%
on 11/24/25
0.2999 -83.33%
on 09/03/25
-0.1400 (-73.68%)
since 08/28/25
52-Week
0.0100 +400.00%
on 11/24/25
0.3800 -86.84%
on 07/10/25
+0.0221 (+79.21%)
since 11/25/24

Most Recent Stories

More News
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference

  -Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope for a Challenging Disease with Limited Therapeutic Options- BOCA RATON, Fla., April 13, 2026 (GLOBE NEWSWIRE)...

LIXT : 3.10 (+5.80%)
LIXTW : 0.0221 (+4.74%)
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year

BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused...

LIXT : 3.10 (+5.80%)
LIXTW : 0.0221 (+4.74%)
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary

BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused...

LIXT : 3.10 (+5.80%)
LIXTW : 0.0221 (+4.74%)
DE LA SOUL-LED “GOOD HEALTH SUMMIT” LAUNCHES FEBRUARY 19 AT MOREHOUSE COLLEGE

Event Sponsored by LIXTE Biotechnology Holdings, Developer of Breakthrough Cancer Therapies Atlanta, GA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Inspired by the music, legacy, and lived experiences...

LIXT : 3.10 (+5.80%)
LIXTW : 0.0221 (+4.74%)
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a...

LIXT : 3.10 (+5.80%)
LIXTW : 0.0221 (+4.74%)
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

--Plans to double the Number of Patients in Study--  --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings,...

LIXT : 3.10 (+5.80%)
LIXTW : 0.0221 (+4.74%)
Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

BOCA RATON, FLA, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a biotech company focused on advancing cancer treatments, today announced that...

LIXT : 3.10 (+5.80%)
LIXTW : 0.0221 (+4.74%)
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25,...

LIXT : 3.10 (+5.80%)
LIXTW : 0.0221 (+4.74%)
LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT, LIXTW), a clinical-stage pharmaceutical company advancing LB-100,...

LIXT : 3.10 (+5.80%)
LIXTW : 0.0221 (+4.74%)
LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

Company underscores clinical execution and confirms advanced negotiations  underway on acquisition of complementary oncology assets BOCA RATON, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LIXTE...

LIXT : 3.10 (+5.80%)
LIXTW : 0.0221 (+4.74%)

Business Summary

Lixte Biotechnology Holdings Inc. is a drug discovery company which uses biomarker technology to identify enzyme targets associated with serious common diseases. The company's product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents...

See More

Key Turning Points

3rd Resistance Point 0.1035
2nd Resistance Point 0.0868
1st Resistance Point 0.0544
Last Price 0.0221
1st Support Level 0.0053
2nd Support Level N/A
3rd Support Level N/A

See More

52-Week High 0.3800
Fibonacci 61.8% 0.2387
Fibonacci 50% 0.1950
Fibonacci 38.2% 0.1513
Last Price 0.0221
52-Week Low 0.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.